SAN DIEGO, CA and PHILADELPHIA, PA — BioAtla, Inc. and Context Therapeutics Inc. have entered into a significant agreement, granting Context an exclusive, worldwide license to develop and commercialize BioAtla’s BA3362, an innovative cancer treatment targeting Nectin-4 and CD3 to address solid tumors. This strategic collaboration allows Context to manage all related development and commercialization processes.
Jay M. Short, Ph.D., CEO of BioAtla, remarked, “With the successful out-licensing of BA3362 to Context, we will continue to focus on execution of our lead clinical CAB programs, while ensuring the potential advancement of BA3362 under the leadership of a seasoned team.” This move aligns with BioAtla’s strategy to enhance shareholder value through non-dilutive means.
Martin Lehr, CEO of Context, stated, “This transaction is consistent with our focus on building a pipeline of TCE assets through strategic in-licensing or acquisition.” He emphasized Nectin-4 as a priority target due to its prevalence in solid tumors and the challenges of resistance with existing therapies.
The agreement includes potential payments to BioAtla totaling up to $133.5 million, featuring $15 million in upfront and near-term milestones, with additional payments contingent on clinical and commercial achievements. BioAtla will also receive tiered royalties on net sales, reflecting the collaboration’s potential financial impact.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.